Medtronic received FDA approval for the Affera mapping and ablation system and Sphere-9 catheter, which can deliver both PFA ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced United States Food and Drug ...

Medtronic (MDT) announced FDA approval of the Affera Mapping and Ablation System with Sphere-9 Catheter, an all-in-one, high-density mapping ...

Medtronic said the Food and Drug Administration approved its Affera mapping and ablation system with sphere-9 catheter.

Medtronic (NYSE: MDT) announced today that the FDA approved an early feasibility study to evaluate its Affera system for ...

The FDA approved an early feasibility study of Medtronic’s Affera mapping and ablation system and Sphere-9 catheter in ...

The study aims to assess the Catheter and Affera system in patients who have ventricular tachycardia (VT) due to scarring ...

Medtronic plc received U.S. FDA approval to undertake an early feasibility study of its dual-energy Affera cardiac ablation system in sustained ventricular tachycardia. Affera combines both ...

Medtronic is a Dividend Aristocrat with 47 consecutive years of payout growth. The MedTech company exceeded the analyst consensus for revenue and non-GAAP EPS in its fiscal first quarter ...

Two of the top 10 largest medtech companies will partner together on robotic head and spine procedures, with Medtronic looking to link its surgical suite with Siemens Healthineers’ pre- and post ...

Today, Medtronic plc (NYSE:MDT), a leader in medical technology, announced the outcomes of its 2024 Annual General Meeting held on Thursday. Shareholders voted on several key proposals ...

Medtronic has announced US Food and Drug Administration (FDA) approval to conduct an early feasibility study using the Affera Mapping and Ablation System for sustained VT, a serious heart condition.